Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Friday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners dropped their price target on Tonix Pharmaceuticals from $18.00 to $8.00 and set a buy rating on the stock in a research report on Tuesday, August 1st.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.48 on Friday. Tonix Pharmaceuticals has a one year low of $0.43 and a one year high of $9.81. The stock’s fifty day moving average is $0.61 and its 200-day moving average is $1.27. The company has a market capitalization of $11.47 million, a PE ratio of -0.04 and a beta of 2.44.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of TNXP. Two Sigma Investments LP increased its holdings in Tonix Pharmaceuticals by 183.9% during the 1st quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock valued at $36,000 after purchasing an additional 38,991 shares in the last quarter. UBS Group AG increased its holdings in Tonix Pharmaceuticals by 18,868.5% during the 4th quarter. UBS Group AG now owns 67,528 shares of the company’s stock valued at $26,000 after purchasing an additional 67,172 shares in the last quarter. Millennium Management LLC increased its holdings in Tonix Pharmaceuticals by 448.2% during the 2nd quarter. Millennium Management LLC now owns 140,414 shares of the company’s stock valued at $222,000 after purchasing an additional 114,801 shares in the last quarter. Raymond James & Associates acquired a new stake in Tonix Pharmaceuticals during the 4th quarter valued at $65,000. Finally, Virtu Financial LLC increased its holdings in Tonix Pharmaceuticals by 44.8% during the 4th quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock valued at $73,000 after purchasing an additional 58,184 shares in the last quarter. Institutional investors own 5.76% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.